Milatuzumab Stocks List
|2019-12-06||IMMU||MACD Bullish Signal Line Cross||Bullish|
|2019-12-06||IMMU||Expansion Breakout||Bullish Swing Setup|
|2019-12-06||IMMU||New 52 Week Closing High||Bullish|
|2019-12-06||IMMU||Wide Range Bar||Range Expansion|
|2019-12-06||IMMU||New 52 Week High||Strength|
|2019-12-06||STRO||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup|
|2019-12-06||STRO||Crossed Above 50 DMA||Bullish|
Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia.
Milatuzumab was developed by Immunomedics, Inc, (Morris Plains NJ USA).